Plain-English translation of NCT06608420 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Precis-Mel 1 is a research study that analyzes medical records from melanoma patients to build an artificial intelligence tool. The AI learns patterns from thousands of patient cases—including tumor information, genetics, and treatment details—to help doctors better predict which patients might benefit most from specific treatments and what their long-term outcomes might be.
Melanoma is a serious skin cancer, and doctors currently struggle to accurately predict which patients will do well with certain treatments or how long they might survive. This study aims to create a smarter prediction tool using AI that could eventually help doctors make more personalized treatment decisions for melanoma patients.
You likely qualify if…
You likely don't qualify if…
This is not a treatment study—you won't receive any new medication or undergo additional procedures. Instead, researchers will review your existing medical records, including your melanoma diagnosis details, any genetic testing, imaging, and past treatments. The study collects data from 6,000 adult melanoma patients and 120 younger patients to train the AI system, so your participation involves allowing access to your historical medical information.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Spain
Collaborators
Hospital Clinic of Barcelona
Enrollment target
~6,000 participants
Started
March 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Susana Puig Sardà, MD, PhD
Fundacion Clinic per a la Recerca Biomédica
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.